The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Incyte
Stock and Other Ownership Interests - Incyte
A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.
 
Ezra E.W. Cohen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Human Longevity, Inc; Merck; Pfizer
 
Danny Rischin
Research Funding - Amgen; Bristol-Myers Squibb; Genentech/Roche; Merck; Regeneron
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca; Bayer; Boehringer Ingelheim; Exelixis; Genentech/Roche; Incyte; Lilly; MedImmune; Merck; Novartis
 
Jan Baptist Vermorken
Consulting or Advisory Role - Innate Pharma; Merck KGaA; PCI Biotech; Synthon; Vaccinogen
Speakers' Bureau - Merck KGaA; Sanofi
Travel, Accommodations, Expenses - Boehringer Ingelheim; Merck KGaA
 
Yufan Zhao
Employment - Amgen (I); Incyte
Stock and Other Ownership Interests - Incyte
Travel, Accommodations, Expenses - Amgen (I)
 
Hema Gowda
No Relationships to Disclose
 
Joy Yang Ge
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Fan Jin
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Kevin J. Harrington
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); MSD (Inst); Pfizer (Inst)
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer
Research Funding - AstraZeneca (Inst); MSD (Inst)